Alumis Reports Q3 2026 Financial Results; LUMUS Phase 2b Trial in SLE Missed Primary Endpoint in Overall Population
Alumis reported Q3 2026 net loss of $94.9 million versus net loss of $110.8 million in Q3 2025, as R&D expenses declined to $80.8 million from $97.8 million. Revenue was $1.9 million, down slightly from $2.1 million in the prior-year quarter. The Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus (SLE) did not meet primary or secondary endpoints in the overall trial population, though robust clinical responses were observed in a prespecified subgroup of patients with high interferon gene sig...
Read source-backed brief